Mammary Cell News 11.41 October 24, 2019 | |
| |
TOP STORYCirculating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers Researchers showed that circulating tumor cells lines established from breast cancer patients were capable of generating metastases in mice with a pattern recapitulating most major organs from corresponding patients. Genome-wide sequencing analyses of metastatic variants identified semaphorin 4D as a regulator of tumor cell transmigration through the blood-brain-barrier and MYC as a crucial regulator for the adaptation of disseminated tumor cells to the activated brain microenvironment. [Cancer Discov] Abstract | |
EmailAddress&u=https://stemcellpodcast.com/&t=(A)MCN11.41i”> | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Cell Swelling, Softening and Invasion in a Three-Dimensional Breast Cancer Model Using a multicellular mammary cancer organoid model, investigators mapped the spatial and temporal evolution of positions, motions and physical characteristics of individual cells in three dimensions. Compared with cells in the organoid core, cells at the organoid periphery and the invasive front were found to be systematically softer, larger and more dynamic. [Nat Phys] Abstract Fate-Mapping Post-Hypoxic Tumor Cells Reveals a ROS-Resistant Phenotype That Promotes Metastasis The authors demonstrated the ability of the system to fate-map hypoxic cells in 2D, and in 3D spheroids and organoids. They identified distinct gene expression patterns in cells that experienced intratumoral hypoxia in vivo compared to cells exposed to hypoxia in vitro. [Nat Commun] Full Article Investigators report the fabrication of novel peptide-conjugated ligand-targeted nanoliposomes (LTLs) for chemo-photodynamic therapy against HER2-positive breast cancer. The LTL core was utilized for encapsulating doxorubicin for chemotherapy, and methylene blue (MB) attached NaYF4:Yb,Er upconversion nanoparticles for NIR-activated bioimaging and leveraging its visible emission for photoexciting MB for enhanced photodynamic therapy. [Nanoscale] Abstract | Graphical Abstract PREX1 Drives Spontaneous Bone Dissemination of ER+ Breast Cancer Cells Using a novel model of spontaneous bone metastasis derived from human ER+ MCF7 cells, molecular profiling revealed increased PREX1 expression in a cell line established from bone-disseminated MCF7 cells, which were more migratory, invasive, and adhesive in vitro compared with parental MCF7 cells, and this phenotype was mediated by PREX1. [Oncogene] Abstract TFAP2C Regulates Carbonic Anhydrase XII in Human Breast Cancer Utilizing chromatin immunoprecipitation and direct sequencing, scientists showed that carbonic anhydrase XII (CA12) was regulated by AP-2γ through binding with its promoter region in luminal breast cancer cell lines and indirectly through a distal estrogen-responsive region in ERα-positive cell lines by upregulation of ERα. CA12 was transcriptionally silenced in basal breast cancer cell lines through histone deacetylation and CpG methylation of the promoter region and could be re-activated with trichostatin A and/or 5-aza-dC. [Oncogene] Abstract Researchers explored the impact of steroid receptor co-activator inhibitor, other targeted anti-cancer compounds and traditional chemotherapeutic agents on the expression of PD-L1 in four breast cancer cell lines. Results showed that these agents induced PD-L1 expression, yet the magnitude of this induction varied substantially across the different compounds. [Sci Rep] Full Article Investigators used doxorubicin as a therapeutic agent, TNFα as marker and mediator of an inflammatory micro-environment and 17β-estradiol as an agonist of estrogen receptors, known predisposing factor for hormone-driven breast cancer, whose pharmacological inhibition reduces the risk of breast cancer recurrence. [Sci Rep] Full Article Using translational models, scientists showed that androgen receptor (AR)-agonist and tissue-selective AR modulators , but not antagonist, inhibited the proliferation and growth of estrogen receptor (ER)-positive breast cancer cells, patient-derived tissues, and patient-derived xenografts. Ligand-activated AR inhibits wild-type and mutant-ER activity by reprogramming the ER and FOXA1 cistrome and rendering tumor-growth inhibition. [iScience] Abstract | Graphical Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSSingle Peptides and Combination Modalities for Triple Negative Breast Cancer The authors review different aspects of triple negative breast cancer immunotherapies including the host immune system-tumor interactions, the tumor microenvironment, the relevant molecular targets for immunotherapy, and clinical trials in the field are discussed. [J Cell Physiol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSMacroGenics, Inc. announced topline results from the second pre-specified interim overall survival analysis for the Phase III SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. [MacroGenics] Press Release Tilray, Inc. announced it has successfully imported medical cannabis into the United States from Canada in support of a new clinical trial. The study will test the efficacy of medical cannabis in treating patients with breast cancer who are suffering from taxane-induced peripheral neuropathy secondary to treatment with paclitaxel or docetaxel. [Tilray, Inc.] Press Release | |
| |
POLICY NEWSFemale Researchers in Australia Less Likely to Win Major Medical Grants than Males Female scientists in Australia were less likely to win a major type of medical-research grants this year than their male counterparts, despite an overhaul of the country’s science funding that was supposed to address gender inequity. [Nature News] Editorial Trump Names Seven to Revived Presidential Science Advisory Panel Thirty-three months after taking office, President Donald Trump has chosen a group of business leaders to advise him on science and technology policy. [ScienceInsider] Editorial UK Science Minister Says DARPA-Like Agency Is in the Works The UK government is working to establish a “blue sky” funding agency similar to the US Defense Advanced Research Projects Agency, UK science minister Chris Skidmore told the Science and Technology Select Committee of Parliament’s House of Commons. [ScienceInsider] Editorial
| |
EVENTSNEW Translational Cancer Research for Basic Scientists Workshop Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Associate – Breast Cancer In Vivo Modeling (King’s College London) NEW Postdoctoral Scholar – Breast Cancer (The University of Kentucky) Postdoctoral Researcher – Breast and Ovarian Cancer (Curtin University) Research Assistant – Breast and Endocrine Tumors (University of Texas MD Anderson Cancer Center) Postdoctoral Position – Cancer Biology (Memorial Sloan Kettering Cancer Center) Research Scientist – Breast Cancer (The University of Pittsburgh) Postdoctoral Researcher – Nanomedicine and Immunoengineering (University of California San Diego) Project Scientist – Breast and Hematological Tumors (Cedars-Sinai) Postdoctoral Fellow – Breast and Prostate Cancer (Mayo Clinic Comprehensive Cancer Center) Postdoctoral Associate – Immune Responses (The Jackson Laboratory) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|